YKL-40 (Chitinase-3-like protein 1)

Migration, Crosslink

📖

YKL-40 (Chitinase-3-like protein 1)

active

wiki page Created: 2026-04-02T07:20:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-ykl40

📖 Wiki Page

biomarker1695 wordssynced 2026-04-02

YKL-40 (Chitinase-3-like protein 1)

> YKL-40 as neuroinflammatory biomarker for neurodegeneration: microglial activation, clinical utility in AD, PD, MS, and ALS

Overview

flowchart TD YKL40["YKL40"] -->|"biomarker for"| Neuroinflammation["Neuroinflammation"] YKL40["YKL40"] -->|"biomarker for"| Alzheimer_s_disease["Alzheimer's disease"] style YKL40 fill:#4fc3f7,stroke:#333,color:#000

YKL-40 (also known as Chitinase-3-like protein 1 or CHI3L1) is a 39-kDa secreted glycoprotein belonging to the glycoside hydrolase family 18. Unlike true chitinases which have enzymatic activity, YKL-40 is a chitinase-like protein (CLP) lacking catalytic function but retaining chitin-binding properties. It is produced primarily by activated macrophages, microglia, and astrocytes in the CNS, and serves as a robust marker of neuroinflammatory responses in neurodegenerative diseases["@boncoeur_ykl"].

Unlike [GFAP](/biomarkers/gfap) which reflects astrocyte activation, YKL-40 specifically indicates microglial activation and macrophage infiltration, providing complementary information about the innate immune component of neurodegeneration. CSF and blood YKL-40 are elevated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS, and other neuroinflammatory conditions, making it a versatile inflammatory biomarker["@olsson_ykl"].

Biochemistry

YKL-40 Protein Structure

YKL-40 is a member of the chitinase-like protein family with distinctive structural features[@jensen_ykl]:

...

YKL-40 (Chitinase-3-like protein 1)

> YKL-40 as neuroinflammatory biomarker for neurodegeneration: microglial activation, clinical utility in AD, PD, MS, and ALS

Overview

Mermaid diagram (expand to render)

YKL-40 (also known as Chitinase-3-like protein 1 or CHI3L1) is a 39-kDa secreted glycoprotein belonging to the glycoside hydrolase family 18. Unlike true chitinases which have enzymatic activity, YKL-40 is a chitinase-like protein (CLP) lacking catalytic function but retaining chitin-binding properties. It is produced primarily by activated macrophages, microglia, and astrocytes in the CNS, and serves as a robust marker of neuroinflammatory responses in neurodegenerative diseases["@boncoeur_ykl"].

Unlike [GFAP](/biomarkers/gfap) which reflects astrocyte activation, YKL-40 specifically indicates microglial activation and macrophage infiltration, providing complementary information about the innate immune component of neurodegeneration. CSF and blood YKL-40 are elevated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS, and other neuroinflammatory conditions, making it a versatile inflammatory biomarker["@olsson_ykl"].

Biochemistry

YKL-40 Protein Structure

YKL-40 is a member of the chitinase-like protein family with distinctive structural features[@jensen_ykl]:

Primary structure:

383 amino acids, signal peptide (22 aa) + mature protein (361 aa)
Molecular weight: 39,638 Da
Named for its N-terminal YKL sequence and apparent molecular weight

Structural domains:

TIM barrel fold (glycoside hydrolase family 18) — Similar to true chitinases but with altered active site
Chitin-binding domain — Enables interaction with extracellular matrix components
Heparin-binding region — Interacts with proteoglycans and cell surfaces

Key amino acid motifs:

DXDXE sequence (catalytic acid) — Present but non-functional in YKL-40
18 conserved positions compared to active chitinases
Rationally mutated in studies to prevent substrate binding

Cellular Sources

YKL-40 production in the CNS is restricted to specific cell types[@boncoeur_ykl]:

Microglia — Primary source in neurodegeneration:

Baseline: Low/undetectable in resting microglia
Activated: Strong upregulation in pro-inflammatory (M1-like) state
Regional pattern: Higher in areas of active neurodegeneration

Astrocytes — Secondary source:

Reactive astrocytes produce YKL-40 in response to inflammatory cytokines
Particularly elevated in areas of astrogliosis

Macrophages/monocytes — Peripheral contribution:

Infiltrating macrophages at blood-brain barrier breach points
Contributes to blood YKL-40 levels

Neurons — Limited expression:

Not a primary neuronal product
Some reports of neuronal YKL-40 in specific conditions

Regulation of YKL-40 Expression

Multiple signaling pathways drive YKL-40 upregulation[@boncoeur_ykl]:

IL-6 family cytokines (IL-6, LIF, CNTF) — Potent inducers via STAT3
TGF-beta — Moderate induction
IFN-gamma — Synergizes with IL-6
Lipopolysaccharide (LPS) — Strong induction via TLR4
Amyloid-beta — Direct activation of microglial YKL-40 production

Pathophysiological Role

Neuroinflammation in Neurodegeneration

YKL-40 elevation reflects the prominent neuroinflammatory component of neurodegenerative diseases[@boncoeur_ykl]:

Alzheimer's Disease[@olsson_ykl]:

YKL-40 correlates with amyloid and tau pathology burden
Reflects microglial activation around amyloid plaques (TREM2-dependent responses)
Higher levels associated with faster disease progression
Independent of amyloid/tau biomarkers, providing complementary information

Parkinson's Disease[@huang_ykl]:

YKL-40 elevated in PD CSF compared to controls
Correlates with disease severity and duration
May reflect microglial activation in substantia nigra
Helps distinguish PD from atypical parkinsonian syndromes

Multiple Sclerosis[@comabella_ykl]:

YKL-40 is one of the best-validated CSF inflammatory markers in MS
Elevated during active demyelination
Predicts conversion from CIS to clinically definite MS
Higher in progressive MS subtypes

ALS[@beyer_ykl]:

YKL-40 elevated in ALS CSF, reflecting neuroinflammation
Correlates with disease progression rate
May indicate microglial involvement in motoneuron degeneration
Independent of neurofilament markers

Mechanisms of YKL-40 Release

CSF YKL-40 elevation occurs through[@jensen_ykl]:

Microglial activation — Upregulated YKL-40 secreted into extracellular space

Astrocyte reactivity — Additional source during neuroinflammation

Cell death — Release from activated cells undergoing death

Peripheral spillover — Blood-brain barrier disruption allows plasma leakage

Exosome secretion — YKL-40 packaged in extracellular vesicles

YKL-40 vs GFAP

These two astroimmune biomarkers provide complementary information[@boncoeur_ykl]:

| Feature | YKL-40 | GFAP |
|---------|--------|------|
| Primary cell source | Activated microglia | Reactive astrocytes |
| Specificity | Neuroinflammation | Astrogliosis |
| AD sensitivity | Moderate | High |
| MS sensitivity | High | Moderate |
| PD sensitivity | Moderate | Low |
| ALS sensitivity | Moderate | Low |

Clinical Utility

Alzheimer's Disease

CSF YKL-40 in AD[@sutphen_ykl]:

| Comparison | AUC | Notes |
|------------|-----|-------|
| AD vs CN | 0.75-0.82 | Moderate accuracy |
| AD vs FTD | 0.70-0.76 | Lower than p-tau/tau biomarkers |
| MCI-AD vs stable MCI | 0.72-0.78 | Moderate predictive value |
| AD vs DLB | 0.68-0.74 | Limited discrimination |

YKL-40 provides inflammatory context to amyloid and tau biomarkers but is not suitable as a standalone diagnostic marker.

Prediction of progression[@sutphen_ykl]:

Higher baseline YKL-40 predicts faster cognitive decline
Rate of increase correlates with brain atrophy
Combined with p-tau181 and NfL improves prognostic models

Parkinson's Disease

CSF YKL-40 in PD[@hooton_ykl]:

| Comparison | AUC | Notes |
|------------|-----|-------|
| PD vs CN | 0.72-0.78 | Moderate accuracy |
| PD vs PSP | 0.68-0.74 | Distinguishes some atypical parkinsonisms |
| PD vs MSA | 0.65-0.72 | Limited discrimination |
| PD dementia vs PD | 0.70-0.76 | Associates with cognitive decline |

Multiple Sclerosis

CSF YKL-40 as MS biomarker[@correll_ykl]:

| Comparison | AUC | Notes |
|------------|-----|-------|
| MS vs CN | 0.78-0.85 | Good inflammatory marker |
| MS vs other dementia | 0.70-0.78 | Limited |
| CIS to MS conversion | 0.74-0.80 | Predicts progression |
| Progressive vs relapsing | 0.76-0.82 | Higher in progressive MS |

Clinical applications in MS:

Risk stratification after first demyelinating event
Monitoring disease activity and treatment response
Surrogate marker for intrathecal inflammation
Prognostic indicator for disability progression

Frontotemporal Dementia

CSF YKL-40 in FTD[@karlsen_ykl]:

Elevated in FTD-TDP compared to controls
Higher in FTD than in AD (in some cohorts)
May help distinguish FTD inflammatory component
Correlates with disease severity

ALS

CSF YKL-40 in ALS[@zhang_ykl]:

| Comparison | AUC | Notes |
|------------|-----|-------|
| ALS vs CN | 0.75-0.82 | Moderate accuracy |
| ALS vs mimics | 0.70-0.76 | Limited |
| Fast vs slow progression | 0.68-0.74 | Higher in rapid progressors |

Analytical Methods

Immunoassays

YKL-40 is measured using validated immunoassays[@boncoeur_ykl]:

| Platform | Detection | Notes |
|----------|-----------|-------|
| ELISA (commercial kits) | 20-1000 pg/mL | Research standard |
| MSD | 1-1000 pg/mL | Multiplex capability |
| Simoa | 0.1-100 pg/mL | Higher sensitivity |
| Luminex | 10-10000 pg/mL | Flexibility |

Sample Considerations

CSF YKL-40 measurement:

Minimal contamination from blood allows reliable measurement
Blood YKL-40 also measurable but peripheral inflammation contributes
Pre-analytical variables similar to other CSF biomarkers

Cutoff Values

CSF YKL-40 (platform-dependent):

| Concentration | Interpretation | Notes |
|--------------|----------------|-------|
| <100 ng/mL | Normal | Cognitively unimpaired young |
| 100-150 ng/mL | Borderline | Requires clinical correlation |
| >150 ng/mL | Elevated | Indicates neuroinflammation |

Blood YKL-40:

Higher concentrations than CSF due to peripheral production
Less specific for CNS pathology
Useful for systemic inflammatory monitoring

Limitations

Specificity Limitations

YKL-40 is not disease-specific[@boncoeur_ykl]:

Elevated in multiple neuroinflammatory conditions
Peripheral inflammation can elevate blood levels
Cannot distinguish between different inflammatory etiologies

Performance Limitations

Compared to core AD biomarkers:

Lower AUC than p-tau181, p-tau217 for AD diagnosis
Not suitable as standalone diagnostic marker
Requires interpretation within clinical context

Confounding Factors

| Factor | Effect | Notes |
|--------|--------|-------|
| Age | Increases with normal aging | Age-adjusted cutoffs |
| Peripheral infection | Elevates blood YKL-40 | CNS-specific requires CSF |
| Autoimmune disease | Elevates YKL-40 | Systemic inflammation |
| Trauma | Acute elevation | Recent TBI confounds |

Research Applications

Microglial Activation Imaging

TSPO PET studies show YKL-40 correlates with microglial activation[@victor_ykl]:

YKL-40 CSF levels correlate with TSPO binding in some regions
Indicates microglial burden in AD and other conditions
Complements grey matter atrophy measures

Mechanistic Insights

YKL-40 provides insights into neuroinflammation mechanisms[@brugge_ykl]:

Direct evidence of microglial activation in human disease
Temporal relationship with other biomarkers
Animal models show YKL-40 upregulation in neurodegeneration paradigms

Clinical Trial Applications

In clinical trials[@boncoeur_ykl]:

Pharmacodynamic marker for anti-inflammatory therapies
Enrichment biomarker for trials targeting microglia
Secondary endpoint for immunomodulatory interventions

Summary

YKL-40 is a validated CSF and blood biomarker that specifically reflects microglial activation and neuroinflammation in neurodegenerative diseases. Key points:

Biochemistry: Chitinase-like protein 1, 39 kDa, produced by activated microglia and astrocytes
Clinical performance: AUC 0.72-0.82 for AD detection; useful in MS, PD, ALS, FTD
Cutoff values: CSF >150 ng/mL indicates elevated neuroinflammation
Clinical utility: Neuroinflammation monitoring, disease progression prediction, clinical trial endpoint
Strengths: Direct microglial marker, MS diagnostic utility, complements other biomarkers
Limitations: Non-specific, lower diagnostic accuracy than core AD biomarkers

YKL-40 provides essential information about the neuroinflammatory axis of neurodegeneration that is not captured by amyloid, tau, or axonal markers.

[Glial Fibrillary Acidic Protein (GFAP)](/biomarkers/gfap) — Astrocyte marker; complements YKL-40
[Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light) — Axonal degeneration; independent of YKL-40
[Phosphorylated Tau 181 (p-tau181)](/biomarkers/csf-pta181) — Tau pathology; combined with YKL-40
[Microglial Activation in Neurodegeneration](/mechanisms/microglial-activation-neurodegeneration) — Mechanism page for microglial pathology
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms-comparison) — Mechanism page for inflammatory pathways

References

[Boncoeur et al., YKL-40 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34065781/)

[Olsson et al., YKL-40 in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30628743/)

[Schmidt et al., YKL-40 and neuroinflammation in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35263569/)

[Matczak et al., YKL-40 in CSF from AD and MS patients (2012)](https://pubmed.ncbi.nlm.nih.gov/22209124/)

[Corell et al., YKL-40 in progressive MS (2018)](https://pubmed.ncbi.nlm.nih.gov/29574776/)

[Beyer et al., YKL-40 in ALS CSF (2019)](https://pubmed.ncbi.nlm.nih.gov/30989443/)

[Huang et al., YKL-40 in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35416485/)

[Victor et al., YKL-40 and neuroinflammation imaging (2021)](https://pubmed.ncbi.nlm.nih.gov/34426581/)

[Comabella et al., YKL-40 in multiple sclerosis (2010)](https://pubmed.ncbi.nlm.nih.gov/21061395/)

[Karlsen et al., YKL-40 in FTD spectrum (2019)](https://pubmed.ncbi.nlm.nih.gov/31201475/)

[Jensen et al., YKL-40 and microglial activation (2013)](https://pubmed.ncbi.nlm.nih.gov/24330368/)

[Connor et al., YKL-40 CSF in healthy aging (2020)](https://pubmed.ncbi.nlm.nih.gov/31816449/)

[Sutphen et al., YKL-40 as biomarker for AD progression (2022)](https://pubmed.ncbi.nlm.nih.gov/36239936/)

[Brugge et al., YKL-40 in rodent models of neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30993878/)

[Hooton et al., YKL-40 in DLB and PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37376951/)

[Chen et al., YKL-40 in traumatic brain injury (2020)](https://pubmed.ncbi.nlm.nih.gov/31684766/)

[Zhang et al., YKL-40 in ALS progression (2023)](https://pubmed.ncbi.nlm.nih.gov/37342244/)

📖 View canonical wiki page →

Related Entities

biomarkers-ykl40

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-ykl40
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9e2b09e7dde3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-ykl40'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

24

Outgoing

38

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

YKL-40 (Chitinase-3-like protein 1)

YKL-40 (Chitinase-3-like protein 1)

Overview

Biochemistry

YKL-40 Protein Structure

YKL-40 (Chitinase-3-like protein 1)

Overview

Biochemistry

YKL-40 Protein Structure

Cellular Sources

Regulation of YKL-40 Expression

Pathophysiological Role

Neuroinflammation in Neurodegeneration

Mechanisms of YKL-40 Release

YKL-40 vs GFAP

Clinical Utility

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Frontotemporal Dementia

ALS

Analytical Methods

Immunoassays

Sample Considerations

Cutoff Values

Limitations

Specificity Limitations

Performance Limitations

Confounding Factors

Research Applications

Microglial Activation Imaging

Mechanistic Insights

Clinical Trial Applications

Summary

References

💬 Discussion

📗 Cite This Artifact

YKL-40 (Chitinase-3-like protein 1)

YKL-40 (Chitinase-3-like protein 1)

Overview

Biochemistry

YKL-40 Protein Structure

YKL-40 (Chitinase-3-like protein 1)

Overview

Biochemistry

YKL-40 Protein Structure

Cellular Sources

Regulation of YKL-40 Expression

Pathophysiological Role

Neuroinflammation in Neurodegeneration

Mechanisms of YKL-40 Release

YKL-40 vs GFAP

Clinical Utility

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Frontotemporal Dementia

ALS

Analytical Methods

Immunoassays

Sample Considerations

Cutoff Values

Limitations

Specificity Limitations

Performance Limitations

Confounding Factors

Research Applications

Microglial Activation Imaging

Mechanistic Insights

Clinical Trial Applications

Summary

Related Biomarkers

References

💬 Discussion